N/A
Completed N=151
Systemic Lupus Erythematous and Heart Conduction Disorders
Lupus Erythematosus, Systemic · atrioventricular block · Sudden Death
Source: ClinicalTrials.gov NCT02162992 ↗
Enrolled (actual)
151
Serious AEs
0.0%
Results posted
Oct 2019
Primary outcomePrimary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec
Summary
Connective tissue diseases have been related to heart conduction disorders. The anti-Ro/SSA antibodies are thought to have a pathogenic role, and they most prevalent in systemic lupus erythematous (SLE). The aim of this study is to evaluate the relationship between SLE, arrhythmias and its serologic profile.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile |
89.22; 91.41; 145.68; 146.72 | — |
| SECONDARY QT and Corrected QT Intervals |
420.74; 421.33; 8.25; 6.81 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with SLE diagnosis, according to SLE diagnostic criteria.
Exclusion Criteria
- Patients with previous cardiac diseases (ischemic heart disease, hypertrophic cardiomyopathy, dilated cardiomyopathy, valvular heart disease)
- Clinical history of heart surgery or ablation procedures
- Clinical history of other conditions that affect heart conduction:
- Steinert Disease
- Lyme Disease
- Chagas Disease
- Hypothyroidism
Data sourced from ClinicalTrials.gov (NCT02162992). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.